What is Novavax's revenue?

Novavax (NVAX) generated $596.3M in revenue over the trailing twelve months, down 52.5% year over year.

Is Novavax profitable?

Novavax is not currently profitable: it reported a net loss of $87.8M over the trailing twelve months, a -14.7% net margin.

What are Novavax's profit margins?

Gross margin is 85.0% and operating margin is -13.1%, with a -14.7% net margin.

What is Novavax's earnings per share?

Novavax's diluted EPS over the trailing twelve months is $-0.64.

Where does Novavax's income statement data come from?

Every line is extracted from Novavax's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Novavax NVAX Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Total revenue	$596.34M-46.9%	$1.12B+5.5%	$1.06B-1.3%	$1.08B-14.0%	$1.25B+84.0%
Total cost of revenue	$89.62M+22.7%	$73.04M-16.6%	$87.61M-30.9%	$126.73M-19.6%	$157.65M-22.2%
Gross profit	$506.72M-51.8%	$1.05B+7.5%	$977.05M+2.6%	$951.99M-13.2%	$1.1B+129%
Gross margin	85%-8.5pp	93.5%+1.7pp	91.8%+3.5pp	88.3%+0.8pp	87.4%+17.2pp
Research and development	$348.86M+1.9%	$342.32M-7.7%	$370.82M+3.1%	$359.71M-7.2%	$387.43M-1.0%
Selling, general and administrative	$138.17M-12.3%	$157.48M-21.9%	$201.7M-16.2%	$240.79M—	——
Total costs & expenses	$674.49M+0.6%	$670.68M-11.4%	$757.17M+4.1%	$727.23M-13.8%	$843.55M-9.4%
Operating income	-$78.15M-117%	$452.8M+47.3%	$307.49M-12.5%	$351.49M-14.6%	$411.41M+265%
Operating margin	-13.1%-53.4pp	40.3%+11.4pp	28.9%-3.7pp	32.6%-0.2pp	32.8%+69.3pp
Interest expense	$21.73M-3.6%	$22.55M-7.2%	$24.31M+5.4%	$23.06M+6.3%	$21.69M+8.0%
Other income (expense), net	$42.4M+4.4%	$40.63M-8.2%	$44.27M-13.2%	$51.02M+8.9%	$46.84M+15.8%
Income before income taxes	-$86.19M-119%	$442.17M+26.1%	$350.68M-18.7%	$431.39M-11.7%	$488.52M+377%
Income tax expense	$1.65M-11.5%	$1.87M-79.1%	$8.94M+4.4%	$8.56M-12.8%	$9.82M-9.8%
Net income	-$87.84M-120%	$440.3M+28.8%	$341.75M-19.2%	$422.82M-11.7%	$478.7M+355%
Net margin	-14.7%-53.9pp	39.2%+7.1pp	32.1%-7.1pp	39.2%+1.1pp	38.1%+65.6pp
Diluted earnings per share	-$0.64-127%	$2.35+32.0%	$1.78-21.6%	$2.27-14.0%	$2.64+297%
EBITDA	-$55.81M-112%	$480.41M+40.3%	$342.49M-12.8%	$392.61M-13.9%	$456.1M+328%
EBITDA margin	-9.4%-52.1pp	42.8%+10.6pp	32.2%-4.2pp	36.4%+0.1pp	36.3%+65.7pp
EBIT	-$78.15M-117%	$452.8M+47.3%	$307.49M-12.5%	$351.49M-14.6%	$411.41M+265%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Novavax.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Novavax's revenue?: Novavax (NVAX) generated $596.3M in revenue over the trailing twelve months, down 52.5% year over year.
Is Novavax profitable?: Novavax is not currently profitable: it reported a net loss of $87.8M over the trailing twelve months, a -14.7% net margin.
What are Novavax's profit margins?: Gross margin is 85.0% and operating margin is -13.1%, with a -14.7% net margin.
What is Novavax's earnings per share?: Novavax's diluted EPS over the trailing twelve months is $-0.64.
Where does Novavax's income statement data come from?: Every line is extracted from Novavax's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.